Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012

BMC Infectious Diseases

Reinhard Zbinden¹  Rainer Weber²  Jürg Meyer³  Severin Läuchli³  Paula Hauser²  Maria DG de Melo Oliveira¹  Helen Kovari² 

[1]Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland

[2]Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

[3]Division of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

关键词: Cephalosporins;    Antimicrobial resistance;    Gonorrhoea;    Neisseria gonorrhoeae;   

Others  :  1135741
DOI  :  10.1186/1471-2334-13-603

 received in 2013-09-23, accepted in 2013-12-18,  发布年份 2013

【 摘 要 】

Background

Neisseria gonorrhoeae can rapidly develop resistance to antimicrobial agents. Over the last years, decreased gonococcal susceptibility to third-generation cephalosporins, especially cefixime, emerged worldwide. Therefore, current international guidelines recommend dual therapy for gonorrhoea with ceftriaxone plus either azithromycin or doxycycline. Gonococcal susceptibility data in Switzerland are sparse.

Methods

We investigated the prevalence of antibiotic susceptibility of N. gonorrhoeae in specimens collected between 1990 and 2012 at the University of Zurich, Switzerland. Minimum inhibitory concentrations (MICs) for cefixime, ceftriaxone, ciprofloxacin, and penicillin were determined by Etests. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used to define reduced susceptibility.

Results

A total of 320 isolates were tested. Between 1990 and 2006 all tested samples were susceptible to both cephalosporins. Subsequently, the prevalence of elevated MICs for cefixime increased to 10.4% (2007/2008), 11.5% (2009/2010), and 11.4% (2011/2012); and for ceftriaxone to 2.4% (2007/2008), 4.7% (2009/2010), and 0% (2011/2012), respectively. The prevalence of resistance to ciprofloxacin (72.7%) and penicillin (22.7%) was high in 2011/2012.

Conclusions

Decreasing susceptibility of N. gonorrhoeae to third-generation cephalosporins in Switzerland supports treatment recommendations with ceftriaxone plus azithromycin or doxycycline. Health-care providers need to be aware of possible treatment failures with cephalosporins. Continued surveillance of gonococcal antimicrobial resistance is essential.

【 授权许可】

   
2013 Kovari et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Marrazzo JM, Handsfield HH, Sparling PF: Neisseria gonorrhoeae. In Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th edition. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone Elsevier; 2010.
• [2]Fleming DT, Wasserheit JN: From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999, 75(1):3-17.
• [3]Stoltey JE, Barry PM: The use of cephalosporins for gonorrhea: an update on the rising problem of resistance. Expert Opin Pharmacother 2012, 13(10):1411-1420.
• [4]Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, Tamaki M, Maeda S: Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007, 13(8):1275-1277.
• [5]Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, Tapsall JW: Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008, 52(10):3564-3567.
• [6]Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H: Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010., 15(47)
• [7]Ison CA, Hussey J, Sankar KN, Evans J, Alexander S: Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011., 16(14)
• [8]Unemo M, Golparian D, Stary A, Eigentler A: First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011., 16(43)
• [9]Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE: Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309(2):163-170.
• [10]Lewis DA, Sriruttan C, Muller EE, Golparian D, Gumede L, Fick D, de Wet J, Maseko V, Coetzee J, Unemo M: Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68(6):1267-1270.
• [11]Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D: Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009, 58(Pt 5):683-687.
• [12]Unemo M, Golparian D, Hestner A: Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, 2010. Euro Surveill 2011., 16(6)
• [13]Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M: Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55(7):3538-3545.
• [14]Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P: High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56(3):1273-1280.
• [15]Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C: Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012, 67(8):1858-1860.
• [16]Unemo M: The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy. Euro Surveill 2012., 17(47)
• [17]Update to CDC’s Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections MMWR Morb Mortal Wkly Rep 2012, 61(31):590-594.
• [18]Bundesamt für Gesundheit. 2013. http://www.bag.admin.ch/k_m_meldesystem/00733/00813/index.html?lang=de webcite. Accessed May 4, 2013
• [19]Le Lin B, Pastore R, Liassine N, Aramburu C, Sudre P: A new sexually transmitted infection (STI) in Geneva? Ciprofloxacin-resistant Neisseria gonorrhoeae, 2002–2005. Swiss Med Wkly 2008, 138(15–16):243-246.
• [20]World Health Organization (WHO): Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf webcite
• [21]Breakpoint tablets for interpretation of MICs and zone diameters: version 3.1. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/clinical_breakpoints/ webcite. Accessed April 30
• [22]Gonococcal antimicrobial susceptibility surveillance in Europe 2010 Stockholm: ECDC 2012:European Centre for Disease Prevention and Control (ECDC). Available from: http://ecdc.europa.eu/en/publications/Publications/1206-Gonococcal-AMR.pdf webcite
• [23]CDC Grand rounds: the growing threat of multidrug-resistant gonorrhea MMWR Morb Mortal Wkly Rep 2013, 62(6):103-106.
• [24]Fenton KA, Ison C, Johnson AP, Rudd E, Soltani M, Martin I, Nichols T, Livermore DM: Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 2003, 361(9372):1867-1869.
• [25]Tanaka M, Nakayama H, Notomi T, Irie S, Tsunoda Y, Okadome A, Saika T, Kobayashi I: Antimicrobial resistance of Neisseria gonorrhoeae in Japan, 1993–2002: continuous increasing of ciprofloxacin-resistant isolates. Int J Antimicrob Agents 2004, 24(Suppl 1):S15-22.
• [26]Hsueh PR, Tseng SP, Teng LJ, Ho SW: High prevalence of ciprofloxacin-resistant Neisseria gonorrhoeae in Northern Taiwan. Clin Infect Dis 2005, 40(1):188-192.
• [27]Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections MMWR Morb Mortal Wkly Rep 2007, 56(14):332-336.
• [28]Tapsall JW, Limnios EA, Murphy D: Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997 2006. J Antimicrob Chemother 2008, 61(1):150-155.